First metabolically activated molecular glue degrader may target cancer cells under oxidative stress

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.

The top 3

  1. Immunotherapy's Transformative Impact: Immunotherapy, which harnesses the body's immune system to fight cancer, became a reality with interferon approval in 1986 and has since expanded to include monoclonal antibodies, checkpoint inhibitors, and CAR T-cell therapy.
  2. Targeted Therapies Revolutionize Precision: Targeted therapies, such as kinase inhibitors introduced in the early 2000s and the first targeted cancer drug Rituximab in 1997, specifically interfere with molecules involved in cancer growth and progression, leading to more precise treatments.
  3. Precision Medicine and Gene Therapy Advancements: Precision oncology, which maps molecular drivers of cancer to tailor treatments, along with gene therapies like CAR T-cell therapy that genetically engineer a patient's T cells, represent significant progress in personalized cancer care.

Sources

Open the full topic